Jun 2026 (Q2 FY26) — Aug 12, 2026
Inovio Q2 FY26 — INO-3107 BLA Progress and Launch Preparations
Read the full callInovio (INO) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Inovio earnings: last reported Wed, 12 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 0.00 | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. The year-earlier figure was zero or a loss, so no percentage is shown. | |
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | -6.0 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$1.04 +5.05% · +$0.05
Performance −57.4% 1Y
1Y: $2.44 on 14 Oct 2025 → $1.04. High $2.6 (17 Dec 2025), low $0.66 (30 Jul 2026).
- Previous close
- $0.99
- 52-week range
- $0.66 – $2.6
- One year
- −59.06%
Overview
- Symbol
- INO
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Inovio earnings calls (INO)
Financials
What the filings say
Net profit, year on year: +74% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | -27 | -20 | -25 | -23 | -21 | -17 | -22 | -19 |
| Operating margin | — | −17410.8% | −38337.0% | — | — | — | — | — |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | — | — |
| Net profit | -25 | -19 | -20 | -24 | -45 | 4 | -20 | -6 |
| EPS ($ per share) | -0.89 | — | -0.51 | -0.61 | -0.87 | — | -0.28 | -0.07 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -620 | -740 | -906 | -1,210 | -1,488 | -1,623 | -1,730 | -1,815 |
| Total liabilities | 44 | 139 | 79 | 96 | 126 | 54 | 45 | 50 |
| Fixed assets | 16 | 13 | 11 | 17 | 8 | 5 | 4 | 3 |
| Investments | 58 | 67 | 161 | 330 | 207 | 131 | 28 | 14 |
| Total assets | 131 | 144 | 540 | 496 | 349 | 171 | 113 | 74 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -74 | -98 | -178 | -216 | -216 | -124 | -104 | -89 |
| Cash from investing | 42 | -9 | -59 | -175 | 110 | 87 | 104 | 14 |
| Cash from financing | 31 | 105 | 465 | 211 | 82 | 5 | 51 | 53 |
| Net cash flow | -0 | -1 | 229 | -180 | -25 | -32 | 52 | -22 |
| Capital expenditure | -2 | -1 | -2 | -1 | -1 | -0 | -0 | -0 |
| Free cash flow | -76 | -99 | -179 | -217 | -217 | -125 | -105 | -89 |
Insider filings
34 filings between Feb 26, 2026 and May 20, 2026.
Open market
decisions to buy or sellNobody bought or sold INO on the open market in this window. The filings below are 18 option exercises and 16 tax withholdings.
Compensation
not trading decisions- 18
- Option exercise — converted options into shares
- 16
- Tax withheld — shares kept back by the company to cover tax
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 20, 2026 | KIES PETER CFO | Option exercise | 8,700 | — |
| May 20, 2026 | KIES PETER CFO | Tax withheld | 4,688 | $5.8K |
| May 20, 2026 | Humeau Laurent Chief Scientific Officer | Option exercise | 6,027 | — |
| May 20, 2026 | Humeau Laurent Chief Scientific Officer | Tax withheld | 2,163 | $2.7K |
| May 20, 2026 | Shea Jacqueline Elizabeth Chief Executive Officer | Option exercise | 28,296 | — |
| May 20, 2026 | Shea Jacqueline Elizabeth Chief Executive Officer | Tax withheld | 12,306 | $15.1K |
| May 20, 2026 | Sumner Michael John Chief Medical Officer | Option exercise | 9,450 | — |
| May 20, 2026 | Sumner Michael John Chief Medical Officer | Tax withheld | 2,693 | $3.3K |
| May 15, 2026 | Shea Jacqueline Elizabeth Chief Executive Officer | Option exercise | 17,744 | — |
| May 15, 2026 | KIES PETER CFO | Option exercise | 4,771 | — |
| May 15, 2026 | KIES PETER CFO | Tax withheld | 2,571 | $3.3K |
| May 15, 2026 | Humeau Laurent Chief Scientific Officer | Option exercise | 4,771 | — |
| May 15, 2026 | Humeau Laurent Chief Scientific Officer | Tax withheld | 1,712 | $2.2K |
| May 15, 2026 | Shea Jacqueline Elizabeth Chief Executive Officer | Tax withheld | 7,717 | $10.0K |
| May 15, 2026 | Sumner Michael John Chief Medical Officer | Option exercise | 2,385 | — |
| May 15, 2026 | Sumner Michael John Chief Medical Officer | Tax withheld | 680 | $884 |
| Mar 31, 2026 | Sumner Michael John Chief Medical Officer | Option exercise | 4,292 | — |
| Mar 31, 2026 | Sumner Michael John Chief Medical Officer | Tax withheld | 1,223 | $2.1K |
| Feb 26, 2026 | KIES PETER CFO | Option exercise | 5,010 | — |
| Feb 26, 2026 | KIES PETER CFO | Tax withheld | 2,965 | $5.3K |
| Feb 26, 2026 | KIES PETER CFO | Option exercise | 10,634 | — |
| Feb 26, 2026 | KIES PETER CFO | Tax withheld | 6,294 | $11.3K |
| Feb 26, 2026 | Weiner David B. Director | Option exercise | 972 | — |
| Feb 26, 2026 | Humeau Laurent Chief Scientific Officer | Option exercise | 5,010 | — |
| Feb 26, 2026 | Humeau Laurent Chief Scientific Officer | Tax withheld | 2,064 | $3.7K |
| Feb 26, 2026 | Humeau Laurent Chief Scientific Officer | Option exercise | 7,366 | — |
| Feb 26, 2026 | Humeau Laurent Chief Scientific Officer | Tax withheld | 3,034 | $5.4K |
| Feb 26, 2026 | Shea Jacqueline Elizabeth Chief Executive Officer | Option exercise | 18,632 | — |
| Feb 26, 2026 | Shea Jacqueline Elizabeth Chief Executive Officer | Tax withheld | 8,057 | $14.4K |
| Feb 26, 2026 | Shea Jacqueline Elizabeth Chief Executive Officer | Option exercise | 28,401 | — |
| Feb 26, 2026 | Shea Jacqueline Elizabeth Chief Executive Officer | Tax withheld | 13,657 | $24.4K |
| Feb 26, 2026 | Sumner Michael John Chief Medical Officer | Option exercise | 5,010 | — |
| Feb 26, 2026 | Sumner Michael John Chief Medical Officer | Option exercise | 11,550 | — |
| Feb 26, 2026 | Sumner Michael John Chief Medical Officer | Tax withheld | 3,903 | $7.0K |
| Jun 30, 2025 | Sumner Michael John Chief Medical Officer | Option exercise | 2,916 | — |
| May 21, 2025 | Weiner David B. Director | Option exercise | 2,167 | — |
| May 21, 2025 | DANSEY ROGER D Director | Option exercise | 2,167 | — |
| May 21, 2025 | YARNO WENDY L Director | Option exercise | 2,167 | — |
| May 21, 2025 | BENITO SIMON X Director | Option exercise | 2,167 | — |
| May 21, 2025 | Shepard Jay Director | Option exercise | 2,167 | — |
| May 21, 2025 | Miller Ann Calby Director | Option exercise | 2,167 | — |
| May 21, 2025 | Zoth Lota S. Director | Option exercise | 2,167 | — |
| May 10, 2025 | Shea Jacqueline Elizabeth Chief Executive Officer | Option exercise | 5,500 | — |
| May 10, 2025 | Shea Jacqueline Elizabeth Chief Executive Officer | Tax withheld | 2,392 | $4.3K |
| Feb 26, 2025 | Weiner David B. Director | Option exercise | 972 | — |
| Feb 26, 2025 | Weiner David B. Director | Option exercise | 972 | — |
| Feb 26, 2025 | KIES PETER CFO | Option exercise | 3,997 | — |
| Feb 26, 2025 | KIES PETER CFO | Tax withheld | 2,362 | $4.7K |
| Feb 26, 2025 | KIES PETER CFO | Option exercise | 5,010 | — |
| Feb 26, 2025 | KIES PETER CFO | Tax withheld | 2,960 | $5.9K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for INOVIO PHARMACEUTICALS, INC.
Free account. Everything above stays public.
Write why you follow INOVIO PHARMACEUTICALS, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading